Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Fluindione→

Fluindione Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
957-56-2
Molecular formula
C15H9FO2
Molecular weight
240.23 g/mol
Drug class
Vitamin K antagonist (VKA) oral anticoagulantindandione derivative
Mechanism of action
Inhibits vitamin K epoxide reductase complex (VKORC1), reducing regeneration of active vitamin K and limiting gamma-carboxylation of coagulation factors II, VII, IX and X and proteins C and S.
Indications / reported uses
  • Prevention and treatment of thromboembolic disorders, including venous thromboembolism and prevention of stroke in selected patients with atrial fibrillation, in countries where fluindione remains authorised; dose requires INR monitoring and country-specific safety restrictions

Sources: ANSM — Fluindione (Previscan) safety information · NLM MeSH — Fluindione · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Fluindione Environmental Risk Assessment (ERA) (the Fluindione ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.